If you are menopausal and using this medication for hot flashes, watch for these symptoms

AIFA highlights in a note the risk of liver damage induced by a specific drug and new recommendations for monitoring liver function before and during treatment with fezolinetant

Liver function tests (Lft) should be performed before starting treatment with fezolinetant, because severe liver damage has been observed”.

This is what we read in a note just released by AIFA, which reports some damage with the use of Veozah (fezolinetantin fact), which many women resort to for disorders related to menopause such as hot flashes.

Furthermore, the Agency also publishes new recommendations for monitoring liver function before and during treatment.

What is Veozah

It is a new oral treatment recently approved by the FDA to address one of the most common disorders typically associated with menopausedeveloped by Astellas Pharma: the so-called flushes.

Its active ingredient is the first antagonist Not NK3 receptor hormone implicated in the regulation of body temperature at the brain level. By binding to the NK3 receptor, fezolinetant blocks its action, helping to resolve the problem of hot flashes and sweating.

AIFA’s recommendations

Since liver damage has been observed:

Finally, AIFA recommends always keeping under observation signs or symptoms that could be indicative of liver damage such as: